Celldex Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Celldex Therapeutics Inc CLDX.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -81 cents. The mean expectation of eleven analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -75 cents to -58 cents per share.

• Revenue rose 110.3% to $3.19 million from a year ago; analysts expected $828.30 thousand.

• Celldex Therapeutics Inc's reported EPS for the quarter was a loss of 64 cents​.

• The company reported a quarterly loss of $42.12 million.

• Celldex Therapeutics Inc shares had fallen by 18.7% this quarter and lost 30.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 6.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Celldex Therapeutics Inc is $69.00

This summary was machine generated from LSEG data November 7 at 03:09 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)